Published 2023
| Version v1
Publication
Early and Late Response and Glucocorticoid-Sparing Effect of Belimumab in Patients with Systemic Lupus Erythematosus with Joint and Skin Manifestations: Results from the Belimumab in Real Life Setting Study—Joint and Skin (BeRLiSS-JS)
Creators
- MARGHERITA ZEN
- MARIELE GATTO
- Roberto Depascale
- Francesca Regola
- Micaela Fredi
- Laura ANDREOLI
- franco franceschini
- Maria Letizia Urban
- Giacomo Emmi
- Fulvia Ceccarelli
- Fabrizio Conti
- Alessandra Bortoluzzi
- Marcello Govoni
- Chiara Tani
- Marta Mosca
- tania ubiali
- Maria Gerosa
- Enrica P. Bozzolo
- Valentina Canti
- Paolo Cardinaletti
- Armando Gabrielli
- Giacomo Tanti
- Elisa Gremese
- Ginevra De Marchi
- Salvatore De Vita
- serena fasano
- Francesco Ciccia
- Giulia Pazzola
- Carlo Salvarani
- Simone NEGRINI
- Andrea Di Matteo
- ROSSELLA DE ANGELIS
- Giovanni Orsolini
- Maurizio Rossini
- Paola Faggioli
- Antonella Laria
- Matteo Piga
- Alberto Cauli
- Salvatore Scarpato
- Francesca Wanda Rossi
- Amato De Paulis
- Enrico Brunetta
- Angela Ceribelli
- Carlo Selmi
- Marcella Prete
- Vito RACANELLI
- Angelo Vacca
- Elena Bartoloni
- Roberto Gerli
- Elisabetta Zanatta
- Maddalena Larosa
- Francesca Saccon
- Andrea Doria
- Luca Iaccarino
Contributors
Others:
- Zen, Margherita
- Gatto, Mariele
- Depascale, Roberto
- Regola, Francesca
- Fredi, Micaela
- Andreoli, Laura
- Franceschini, Franco
- Letizia Urban, Maria
- Emmi, Giacomo
- Ceccarelli, Fulvia
- Conti, Fabrizio
- Bortoluzzi, Alessandra
- Govoni, Marcello
- Tani, Chiara
- Mosca, Marta
- Ubiali, Tania
- Gerosa, Maria
- Bozzolo, Enrica P.
- Canti, Valentina
- Cardinaletti, Paolo
- Gabrielli, Armando
- Tanti, Giacomo
- Gremese, Elisa
- De Marchi, Ginevra
- De Vita, Salvatore
- Fasano, Serena
- Ciccia, Francesco
- Pazzola, Giulia
- Salvarani, Carlo
- Negrini, Simone
- Di Matteo, Andrea
- DE ANGELIS, Rossella
- Orsolini, Giovanni
- Rossini, Maurizio
- Faggioli, Paola
- Laria, Antonella
- Piga, Matteo
- Cauli, Alberto
- Scarpato, Salvatore
- Wanda Rossi, Francesca
- De Paulis, Amato
- Brunetta, Enrico
- Ceribelli, Angela
- Selmi, Carlo
- Prete, Marcella
- Racanelli, Vito
- Vacca, Angelo
- Bartoloni, Elena
- Gerli, Roberto
- Zanatta, Elisabetta
- Larosa, Maddalena
- Saccon, Francesca
- Doria, Andrea
- Iaccarino, Luca
Description
Aim: To assess the efficacy of belimumab in joint and skin manifestations in a nationwide cohort of patients with SLE. Methods: All patients with skin and joint involvement enrolled in the BeRLiSS cohort were considered. Belimumab (intravenous, 10 mg/kg) effectiveness in joint and skin manifestations was assessed by DAS28 and CLASI, respectively. Attainment and predictors of DAS28 remission (<2.6) and LDA (≥2.6, ≤3.2), CLASI = 0, 1, and improvement in DAS28 and CLASI indices ≥20%, ≥50%, and ≥70% were evaluated at 6, 12, 24, and 36 months. Results: DAS28 < 2.6 was achieved by 46%, 57%, and 71% of patients at 6, 12, and 24 months, respectively. CLASI = 0 was achieved by 36%, 48%, and 62% of patients at 6, 12, and 24 months, respectively. Belimumab showed a glucocorticoid-sparing effect, being glucocorticoid-free at 8.5%, 15.4%, 25.6%, and 31.6% of patients at 6, 12, 24, and 36 months, respectively. Patients achieving DAS-LDA and CLASI-50 at 6 months had a higher probability of remission at 12 months compared with those who did not (p = 0.034 and p = 0.028, respectively). Conclusions: Belimumab led to clinical improvement in a significant proportion of patients with joint or skin involvement in a real-life setting and was associated with a glucocorticoid-sparing effect. A significant proportion of patients with a partial response at 6 months achieved remission later on during follow-up.
Additional details
Identifiers
- URL
- https://hdl.handle.net/11567/1120455
- URN
- urn:oai:iris.unige.it:11567/1120455
Origin repository
- Origin repository
- UNIGE